Impact assessment

Cervical screening HPV self-sampling: impact assessments

Impact assessment and equality impact assessment of human papillomavirus (HPV) self-sampling in the NHS Cervical Screening Programme.

• From: Department of Health and Social Care
• Published: 7 August 2025

Documents

Impact assessment: HPV self-sampling in the NHS Cervical Screening Programme

PDF, 903 KB, 52 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Equality impact assessment: HPV self-sampling in the NHS Cervical Screening Programme

HTML

Details

These impact assessments relate to providing an offer of high-risk human papillomavirus (HPV) self-sampling (self-testing) to under-screened people. ‘Under-screened’ means people who are at least 6 months overdue their last cervical screening.

The impact assessment covers:

• the proposed change to the NHS Cervical Screening Programme and the rationale for it
• economic assessment
• the evidence base
• how the proposed change affects the cervical screening pathway (the steps through the screening process, including invitations, results and retesting or referral)
• monitoring and evaluation

The equality impact assessment covers:

• the intended aims of HPV self-sampling
• evidence for HPV self-sampling
• analysis of impacts
• public engagement
• a summary of analysis
• addressing the impact on equalities
• monitoring and evaluation

Published 7 August 2025